NOVEL DRUG THERAPIES IN INFLAMMATORY BOWEL-DISEASE

Citation
Hs. Debinski et Ma. Kamm, NOVEL DRUG THERAPIES IN INFLAMMATORY BOWEL-DISEASE, European journal of gastroenterology & hepatology, 7(2), 1995, pp. 169-182
Citations number
NO
Categorie Soggetti
Gastroenterology & Hepatology
ISSN journal
0954691X
Volume
7
Issue
2
Year of publication
1995
Pages
169 - 182
Database
ISI
SICI code
0954-691X(1995)7:2<169:NDTIIB>2.0.ZU;2-#
Abstract
This paper reviews the published data on novel drug treatments for inf lammatory bowel disease. Steroids that are topically active or rapidly metabolized have a definite therapeutic role and have fewer long-term side-effects than other steroids. Methotrexate can promote remission in approximately 50% of patients, but is less effective in maintaining remission. Cyclosporin is valuable for treating patients with severe ulcerative colitis but is less valuable for patients with Crohn's dise ase. None of the drugs that modify specific inflammatory mediators hav e proven efficacy but tumour necrosing factor and CD4 antibodies may b e promising. In patients with distal colitis, lignocaine appears to be effective